Birkmayer USA, based in Carlsbad, California business mission is to develop and market safe, reliable, effective products, which will improve the quality of life for all people. CO-E1 (NADH) represents a quantum leap forward in our continued quest to develop the highest quality nutritional supplement products. We recognize the need of proving our products are both safe and effective through sound, quantifiable, scientific principles and clinical research studies...not marketing hype. We have invested millions of dollars in research to achieve Investigative New Drug (IND) status for NADH, enabling us to conduct clinical trials. These clinical studies follow strict Pharmaceutical and Drug testing methodology consisting of double blind crossover, placebo controlled human studies. These studies have been conducted at prestigious medical institutions such as Georgetown University Medical Center.

The company's proprietary manufacturing, marketing and research are based on several solid patents in the nutraceuticals industry. Eight United States patents protect ENADA, including three formulation patents and five patents based on various methods of treatment. Substantial patents have been established, or are pending, in ten European countries, as well as Israel, China, Japan, Canada, Mexico, Taiwan, and Brazil. Overall, over 30 worldwide patents have been issued, or are pending.

For Press Inquiries (i.e., stories, interview requests) contact:

Leslie Kulesza ,
Birkmayer USA
(760) 438 2755
leslie@co-e1.com